Portal de Periódicos da CAPES

Sind Monoaminoxidase-Hemmstoffe bei Disposition zu maligner Hyperthermie kontraindiziert? - Diskussion anhand eines Fallberichts

1996; Georg Thieme Verlag; Volume: 31; Issue: 06 Linguagem: Inglês

10.1055/s-2007-995934

1439-1074

Frank Wappler, A. Köchling, Norbert Roewer,

Alcoholism and Thiamine Deficiency

We report on a young patient with a positive family history for malignant hyperthermia (MH), who was diagnosed as susceptible to MH in our malignant hyperthermia laboratory by the in vitro-contracture test. Prior to the investigation of MH-susceptibility, the patient had been on medication with moclobemide, a monoamine oxidase (MAO) inhibitor, over a period of 13 months for treatment of a hyperactivity disorder. During the therapy with moclobemide no signs of relevant side effects were observed. However, some authors regard MAO-inhibitors as MH-triggering agents. The risk of MH-patients due to the therapy with MAO-inhibitors and the association between MH and the neuroleptic malignant syndrome is discussed in this case report.